论文部分内容阅读
目的分析急性缺血性脑卒中(ACI)患者行阿替普酶联合尤瑞克林、依达拉奉治疗前后血D-二聚体以及C-反应蛋白(hs-CRP)的变化。方法选择本院2016年1月—2017年6月接收的91例ACI患者作为研究对象。将其分为对照A组(30例)、对照B组(30例)、研究组(31例)。研究组患者采用阿替普酶联合尤瑞克林、依达拉奉治疗;对照A组采用尤瑞克林联合依达拉奉治疗;对照B组采用依达拉奉治疗,分析观察三组患者的治疗效果。结果 24 h治疗后,研究组患者的D-二聚体均高于对照A组及B组,研究组hs-CRP为(4.01±0.51)mg/L,均低于对照A组及B组,差异具有统计学意义(P<0.05);对照组A、B组的NIHSS评分均高于研究组,差异具有统计学意义(P<0.05)。结论急性缺血性脑卒中在阿替普酶、依达拉奉及尤瑞克林治疗后hs-CRP有所降低,但D-二聚体有一定升高,可改善预后及神经功能,D-二聚体、hs-CRP与ACI的预后密切相关。
Objective To analyze the changes of serum D-dimer and C-reactive protein (hs-CRP) in patients with acute ischemic stroke (ACI) before and after treatment with alteplase and irreclaim and edaravone. Methods 91 patients with ACI admitted from January 2016 to June 2017 in our hospital were selected as the study objects. They were divided into control group A (30 cases), control group B (30 cases) and study group (31 cases). Patients in the study group were treated with alteplase combined with norepinephrine and edaravone; control group A was treated with norepinephrine combined with edaravone; control group B was treated with edaravone, and the patients in the three groups were analyzed Therapeutic effect. Results After 24 h of treatment, the D-dimer in study group was higher than that in control group A and B group. The hs-CRP in study group was (4.01 ± 0.51) mg / L, which were lower than those in control group A and B group The difference was statistically significant (P <0.05). The NIHSS scores of the control group A and B were higher than that of the study group, the difference was statistically significant (P <0.05). Conclusions Acute ischemic stroke hs-CRP decreased after treatment with alteplase, edaravone and uracil, but D-dimer increased to a certain extent, which could improve the prognosis and neurological function. D - dimer, hs-CRP is closely related with the prognosis of ACI.